Research programme: small molecule-based cancer immunotherapeutics - Apeiron Biologics/Evotec/Sanofi

Drug Profile

Research programme: small molecule-based cancer immunotherapeutics - Apeiron Biologics/Evotec/Sanofi

Alternative Names: TargetImmuniT

Latest Information Update: 17 Aug 2015

Price : $50

At a glance

  • Originator Apeiron Biologics; Evotec AG; Sanofi
  • Class Immunotherapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 10 Aug 2015 Evotec, Apeiron Biologics and Sanofi agree to co-develop small-molecule based immunotherapies for Cancer
  • 10 Aug 2015 Early research in Haematological malignancies in Germany (unspecified route)
  • 10 Aug 2015 Early research in Solid tumours in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top